1. Home
  2. BLFY vs IOVA Comparison

BLFY vs IOVA Comparison

Compare BLFY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLFY
  • IOVA
  • Stock Information
  • Founded
  • BLFY 1939
  • IOVA 2007
  • Country
  • BLFY United States
  • IOVA United States
  • Employees
  • BLFY N/A
  • IOVA N/A
  • Industry
  • BLFY Commercial Banks
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BLFY Finance
  • IOVA Health Care
  • Exchange
  • BLFY Nasdaq
  • IOVA Nasdaq
  • Market Cap
  • BLFY 204.2M
  • IOVA 771.4M
  • IPO Year
  • BLFY N/A
  • IOVA N/A
  • Fundamental
  • Price
  • BLFY $9.61
  • IOVA $1.71
  • Analyst Decision
  • BLFY Hold
  • IOVA Buy
  • Analyst Count
  • BLFY 2
  • IOVA 10
  • Target Price
  • BLFY $11.00
  • IOVA $12.22
  • AVG Volume (30 Days)
  • BLFY 60.3K
  • IOVA 11.8M
  • Earning Date
  • BLFY 07-23-2025
  • IOVA 08-07-2025
  • Dividend Yield
  • BLFY N/A
  • IOVA N/A
  • EPS Growth
  • BLFY N/A
  • IOVA N/A
  • EPS
  • BLFY N/A
  • IOVA N/A
  • Revenue
  • BLFY $41,228,000.00
  • IOVA $212,679,000.00
  • Revenue This Year
  • BLFY $20.14
  • IOVA $86.62
  • Revenue Next Year
  • BLFY $20.20
  • IOVA $69.95
  • P/E Ratio
  • BLFY N/A
  • IOVA N/A
  • Revenue Growth
  • BLFY N/A
  • IOVA 11070.12
  • 52 Week Low
  • BLFY $8.34
  • IOVA $1.64
  • 52 Week High
  • BLFY $11.48
  • IOVA $12.51
  • Technical
  • Relative Strength Index (RSI)
  • BLFY 61.45
  • IOVA 36.89
  • Support Level
  • BLFY $9.20
  • IOVA $1.95
  • Resistance Level
  • BLFY $8.94
  • IOVA $2.47
  • Average True Range (ATR)
  • BLFY 0.23
  • IOVA 0.16
  • MACD
  • BLFY 0.09
  • IOVA -0.00
  • Stochastic Oscillator
  • BLFY 100.00
  • IOVA 6.41

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: